Dodge & Cox Decreases Position in Neurocrine Biosciences

Institutional investor reduces stake in biotech company

Mar. 14, 2026 at 8:09am

Got story updates? Submit your updates here. ›

Dodge & Cox, a major institutional investor, has decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 0.2% during the third quarter, according to a recent SEC filing. The fund now owns 5,556,618 shares of the company's stock, representing a 5.57% ownership stake worth $780 million.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Tracking changes in institutional ownership can provide insights into how major investors view the company's prospects and performance.

The details

According to the filing, Dodge & Cox sold 10,196 shares of Neurocrine Biosciences during the third quarter. The firm continues to hold a sizable position in the company, owning over 5.5 million shares. Neurocrine Biosciences' stock price has fluctuated in recent months, trading between $84 and $160 over the past 52 weeks.

  • Dodge & Cox decreased its position in Neurocrine Biosciences during the third quarter of 2025.

The players

Dodge & Cox

A major institutional investment management firm based in San Francisco.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders, headquartered in San Diego, California.

Got photos? Submit your photos here. ›

The takeaway

The decrease in Dodge & Cox's position in Neurocrine Biosciences reflects the volatility and uncertainty surrounding the biotech sector, but the firm's continued sizable stake suggests it still sees long-term potential in the company's pipeline and product portfolio.